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Summary 
The effect of anti-CD69 monodonal antibodies (mAbs) on the induction of the cytolytic activity 
in different types of lymphoid effector cells has been investigated. Three anti-CD69 mAbs, including 
the reference mAb MLR3 and two new mAbs (c227 and 31C4),  have been used. All cloned 
CD3-CD16 + natural killer (NK) cells belonging to different subsets (as defined by the surface 
expression of GL183 and/or EB6 antigens) were efficiently triggered by anti-CD69 mAbs and 
lysed P815 mastocytoma  ceUs in a redirected killing assay. Triggering of the cytolytic activity 
could also be induced in CD3-CD16-  NK clones, which fail to respond to other stimuli 
(including anti-CD16, anti-CD2 mAbs, or phytohemagglutinin). A similar triggering effect was 
detected in T  call receptor (TCR) 3,/~ + clones belonging to different  subsets. On the other 
hand, anti-CD69 mAbs could not induce triggering of the cytolytic activity in TCR cr  + 
cytolytic dones. Since all thymocytes are known to express CD69 antigen after cell activation, 
we analyzed a series of phenotypically different cytolytic thymocyte populations  and clones for 
their responsiveness to anti-CD69 mAb in a redirected killing assay. Again, anti-CD69 mAb 
triggered TCR 3,/~ + but not TCR ce/~ + thymocytes.  Anti-CD69 mAb efficiently triggered 
the cytolytic activity of "early" thymocytes lines or clones (CD3-4-8-7 +), which lack all other 
known pathways of cell activation. Thus, it appears that CD69 molecules may initiate a pathway 
of activation of cytolytic functions common to a number of activated effector lymphocytes with 
the remarkable exception  of TCR ot/B + cytolytic cells. 
T 
riggering of the cytolytic machinery of human effector 
lymphocytes can be induced by different  stimulatory 
agents including antigens, mitogens, and appropriate mAbs. 
For example, mAbs specific for the CD3/TCK complex (1, 
2) or CD2 molecules (3-5) can mediate triggering of the cyto- 
lytic activity in T lymphocytes expressing either TCR o~//~ 
or  TCR  3'/~.  On  the  other  hand,  activation  of 
CD3-CD16 + NK cells can be induced by anti-CD16 (6-8) 
or anti-CD2 (6, 7) mAbs.  More recently, a new family of 
stimulator)' surface molecules (9, 10) has been identified in 
discrete NK subsets, mAbs to  these molecules,  including 
GL183 and EB6 mAbs, selectively  triggered these NK subsets. 
In addition, a number of triggering molecules are expressed 
at the lymphocyte surface only after cell activation.  Among 
these surface molecules, the CD69 antigen is expressed very 
early after T or NK cell activation (11-13), whereas it is not 
expressed on resting T or NK lymphocytes (11, 14, 15). It 
has been shown that anti-CD69 mAbs mediate T lympho- 
cyte triggering leading to lymphokine production and cell 
proliferation  (13, 16). On the other hand, in conventional 
TCK o~//3  + cytolytic clones, anti-CD69 mAbs failed to in- 
duce cytolytic activity in redirected killing assays (16). 
In the present study, we show that mAbs to CD69 mole- 
cules efficiently trigger the cytolytic machinery of a number 
of peripheral blood or thymus-derived cytolytic clones with 
the remarkable exception  of those expressing or//3 TCKs. 
Materials and Methods 
Isolation and Culture of Lyraphocyte Subsets.  PBL from normal 
volunteers were isolated by FicoU-Hypaque  gradients and subse- 
quently separated  into different subsets by cell sorting and/or treat- 
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Cloning of the various cell subsets was performed under limiting 
dilution  conditions  in the presence of irradiated feeder cells and 
IL-2 (rib2; Cetus Corp., Emeryville, CA), as previously described 
for both T and NK cells (10, 17, 18). 
Production of mAh  5-wk-old  male  BALB/c mice  were  im- 
munized  with  a  cell clone  termed  CES9  (surface phenotype: 
CD3-CD16+CD56 §  as previously described (10). After six in- 
jections,  the mice were splenectomized and immune  splenocytes 
were fused with P3U1 myeloma cells. The screening of hybridoma 
supernatants  was based on the ability to modulate  the cytolytic 
activity of CES9 against the cell line termed P815 used as a source 
of SlCr-labeled target  cells in a 4-h SlCr release assay. According 
to this screening procedure, a hybridoma, termed c227 (IgG1), which 
was able to increase the cytolytic activity of CES9 clone against 
P815 target cells, was isolated and further  subcloned in limiting 
dilution.  The 31C4 mAb (IgG2a) was obtained using a procedure 
similar to that described above. In this case, however, mice were 
immunized with a polyclonal thymocyte population expressing the 
CD3- 4- 8- 7 § 16-  surface phenotype. 
Isolation and Culture of Thymocyte Subsets.  Normal  human 
thymocytes were obtained from thymus fragments removed during 
cardiac surgery of patients  2 mo to 4 yr old,  as described (19). 
CD3 + 3"/5  § thymocytes (1-2% of total thymus)  were obtained 
after positive selection of CD3 § thymic cells using ox-red blood 
cells immunocoated  with OKT3 (anti-CD3  mAb),  as described 
(20), followed by negative depletion  of CD4 + and CD8 + cells 
(19). The resulting cell population was >95% CD3 + TCR -y/c5  § 
as assessed  by immunofluorescence  using anti-TCR #1 mAb. Cloning 
of either  TCR. c~/~ or TCR ~'/~5  § thymic cells was performed 
under  limiting  dilution  conditions  as previously described (21). 
CD1 - 3 - 4- 8 - 7 + thymocytes were obtained after negative deple- 
tion by panning and magnetic beads using anti-CD1 (OKT6), anti- 
CD3 (Leu4), anti-CD4  (Leu3a), and anti-CD8  (Leu2a) mAbs as 
described (22). After this purification, cells recovered were >99.9% 
CD1-3-4-8-.  In  vitro expansion and cloning  of CD1-3-4-8- 
thymic cells was obtained as described (23). 
Functional Analysis of Cytolytic Clones.  The cytolytic activity 
of the various clones was tested in a 4-h 51Cr-release assay, as de- 
scribed above. In all instances, target cells were used at a concentra- 
tion  of 5  x  104/ml and were represented by the P815 murine 
tumor cell line. The E/T ratios ranged from 10:1 to 0.5:1, as indi- 
cated. After titration, DEAE-Sephacel-purified  c227 and 31C4 mAbs 
were used in most experiments at a concentration  of 0.2 ng/ml 
resuspended in 50/~1 of medium. The other mAbs, including MLR3 
(anti-CD69 IgG2a) (24), Leu23 (anti-CD69 IgG1) (kindly provided 
by Dr.  R. Testi, University of EAquila, Italy), c218 (anti-CD56 
IgG1), c127 (anti-CD16  IgG1), KD1 (anti-CD16  IgG2a), JT3A 
(anti-CD3 IgG2a), MAR206 (anti-CD2 IgG1), BB3 (anti-TCR 3'A5 
IgG1), and A13 (anti-TCR 3'/~5 IgG1) were used at doses ranging 
from 2 to 0.2 ng/ml, depending upon preliminary titration experi- 
ments. The above-mentioned mAbs were added at the onset of the 
cytolytic test together with the effector and target  cells. 
Results  and  Discussion 
In these studies we used three different anti-CD69 mAbs, 
including MLR3 (24) and two new mAbs, termed c227 and 
31C4. The reactivity of c227 and 31C4 mAbs with CD69 
molecules was substantiated by biochemical evidence and by 
the pattern of distribution of the corresponding antigen in 
resting and activated lymphocytes (not shown). Thus, under 
reducing conditions, c227, 31C4, or the reference mAb MLR3 
immunoprecipitated  a  28-32-kD  disulphide-linked  dimer, 
which under nonreducing conditions migrated as a diffuse 
60-kD band. In addition, analysis of the pattern of distribu- 
tion in a panel of resting or activated peripheral blood-de- 
rived lymphocyte populations revealed that the c227- and the 
31C4-defined antigen(s)  were expressed only on activated lym- 
phocyte populations and, in all instances,  their distribution 
paralleled the expression of CD69 antigen (as defined by MLR3 
mAb) (not  shown). 
Anti-CD69 mAbs Trigger  the Cytolytic Machinery of Different 
Lymphoid Cell Populations Derived  from Pe@heral  Blood.  Pre- 
vious studies (13, 16) indicated that mAbs specific for CD69 
molecules mediated T cell triggering leading to intracellular 
Ca  2  + increases, and, in the presence of PMA, to lymphokine 
production and cell proliferation. However, no cytolytic ac- 
tivity in CD4 + or CD8 § cytolytic clones could be induced 
in redirected killing assays against P815 target cells using anti- 
CD69 mAbs (16).  It should be noted that c227 and 31C4 
mAbs had been originally selected on the basis of their ability 
to trigger the cytolytic activity of the immunizing cells (the 
NK clone CES9 or a CD3-4-8-7 + thymocyte population) 
in redirected killing assays against P815 target cells. In view 
of these findings, we analyzed the ability of anti-CD69 mAbs 
to induce the cytolytic function in a panel of cytolytic lym- 
phoid  populations  and  clones,  including  NK  cells,  TCR 
c~/~ +,  and TCR qr/# + cells. 
Recently, by the use of mAbs (GL183 and EB6) directed 
to novel triggering surface molecules selectively expressed by 
NK cell fractions, we could define four distinct NK subsets 
characterized by different functional properties (9,  10).  We 
therefore investigated the effect of anti-CD69 mAbs in clones 
representative of the four subsets. As shown in Fig. 1, MLR3 
and c227 mAbs enhanced the cytolytic activity not only of 
the  immunizing  clone  CES9  (belonging  to  the  GL183- 
EB6-  subset) (D), but also triggered NK clones representa- 
tive of the other phenotypic groups (.,t, B,  and C).  In all 
instances,  the anti-CD69 mAb-induced cytolytic activity was 
comparable to that  induced by KD1 mAb (anti-CD16).  A 
similar triggering effect was elicited by other anti-CD69 mAbs, 
including 31C4 and Leu23 mAbs (not shown). Resting NK 
cells do not express CD69 constitutively (11, 14,  15), how- 
ever, CD69 molecules are expressed after short-term culture 
in the presence of IL-2. We therefore investigated the time 
interval required for the acquisition of cytolytic responses to 
triggering  with  anti-CD69  mAb.  In  these  experiments, 
CD3-56 + lymphocyte populations were purified from pe- 
ripheral blood and tested, at different intervals,  for cytolytic 
responses to anti-CD69 mAbs (against P815 target cells).  In 
a representative experiment,  fresh NK cells lysed P815 cells 
in the presence of the (anti-CD16) KD1 mAb (53% lysis at 
3:1 E/T ratio), but not of 31C4 (anti-CD69) or c218 (anti- 
CD56). After 18 h of culture, both anti-CD16 and anti-CD69 
mAbs induced efficient target cell lysis (92% and 59%, respec- 
tively, at 3:1  E/T ratio);  target cell lysis in the absence of 
mAb or in the presence of anti-CD56  mAb was 21%  and 
20%, respectively. After 36 h, the anti-CD69  and the anti- 
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Fig,  re 1.  Enhancements of cytolytic activities by c227 and MLR3 (anti-CD69) mAbs. (A-D) Phenotypically different CD3-CD16 + clones tested 
for cytolytic activity against slCr-labeled P815 target cells at an E/T cell ratio of 1:1. At the onset of the cytolytic test, graded amounts of mAb were 
added to the culture.  (O) c227; (A) MLR3; (it) KD1 (anti-CD16);  ([~) c218 (anti-CD56).  (.4) Clone CA8.5 (GL183  +  , EBr-); (/7) clone CEG76 
(GL183  + , EB6+); (C) done A.M.25 (GL183-, EB6+);  and (D) done CES9 (GL183-, EB6-). (E-H) Phenotypically distinct CD3 + clones tested 
for cytolytic activity against P815 cells at an E/T cell ratio of 5:1. At the onset of the cytolytic test were added graded amounts of either anti-TCg 
(BB3 or A13) mAb (ll) or anti-CD3 0T3A) mAb (A), or anti-CD69 c227 (O) or MLR3 (A) mAb. (E) Clone D1.6 (TCR-7/~ +  , BB3+); (F) clone 
D1.12 (TCR 7/~ +  , A13+); (G) clone 1Bll (TCR. o~13 + ,  CD8+); and (H) done BG2 (TCR ~x/~7  +  , CD8-, CD4-). 
CD16 mAb-mediated lysis was 71% and 82%, respectively 
(22%  and 19%, respectively, in the absence of mAb or in 
the presence of anti-CD56 mAb). These data are in line with 
a previous report by Lanier et al. (11) showing that full ex- 
pression of CD69 molecules at the NK cell surface requires 
•18  h of culture in the presence of rlL,2. 
A minor subset of peripheral blood NK cells is character- 
ized by the absence of surface CD16 antigens and by an in- 
creased expression of CD56 antigen (CD56 bright cells) (25). 
We analyzed  clones derived from this cell subset for their 
responsiveness to anti-CD69 mAbs. These clones maintained 
the original surface phenotype and, similar to most CD16 + 
clones, displayed a strong cytolytic activity against both NK- 
susceptible and NK-resistant target cells. In Table 1, two rep- 
resentative CD3-  CD16-  CD56 + clones,  termed E12 and 
AMK3, were compared to the CD16 + clone CEG76 (10). 
As expected, clones E12 and AMK3 were unresponsive to 
anti-CD16 mAb. In addition, they were poorly stimulated 
by anti-CD2 mAbs (not shown) or PHA. On the contrary, 
in these clones, anti-CD69 mAbs elicited a strong cytolytic 
activity. 
We next analyzed a panel of T  cell clones bearing either 
TCR  or//7  or  TCR 7/8  (Fig.  1).  The two TCR 3,/8 + 
clones (E and F) are representative of the two major subsets 
of TCR 3'/8 + lymphocytes present in peripheral blood (18). 
Thus, clone D.1.6 (E) reacted with BB3 mAb (26) and ex- 
pressed V82, whereas clone D.1.12 (F) was stained by A13 
mAb and thus expressed V81 (27). As shown in Fig. 1, anti- 
CD69 mAbs induced triggering of cytolytic activity in both 
clones. Similar results were obtained in eight additional TCR 
7/~ + clones expressing either V81 or V~2 (not shown). 
Fig.  1, G  and H, shows that anti-CD69 mAbs failed to 
trigger the cytolytic function of two representative TCR 
ol/B + cytolytic clones.  Clone 1BII (G)  is a typical CD4- 
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CD3-CDI6-CD56 + NK Clones 
Stimuli added to the Cytolytic test* 
Clone  None  Anti-CD16  Anti-CD69  PHA 
E12*  18s  18  45  26 
AMK3  19  18  57  28 
CEG76  12  59  62  55 
* The. mAbs used in this  experiment were represented  by KD1 (anti- 
CD16) and 31C4 (anti-CD69), used at a final concentration of 1 ng/ml. 
PHA was used at a final dilution of 1:1,000  (vol/vol). 
Effector cells were either CD3-16-56+  clones (E12 and AMK3) or a 
conventional CD3-16 +  56 + done (CEG76).  Target cells were represent- 
ed by the P815  mastocytoma cell line. 
5Data  are expressed as a percent specific 5*Cr release at an E/T cell ra- 
tio of 1:1. 
CD8 § cytolytic clone, whereas clone BG2 (H) is an unusual 
CD4-CD8-  TCR oe/3 + clone also characterized by a strong 
non-MHC-restricted cytolytic activity against K562 target 
cells (not shown). That the TCR expressed by clone BG2 
is indeed a TCR cr  was indicated by the reactivity with 
the WT31 mAb and by the biochemical characteristics  of 
immunoprecipitated  TCK molecules. It should be noted that, 
although unresponsive to anti-CD69 mAbs, the cytolytic ac- 
tivity of both TCR ot/[3 + clones against P815 cells could 
be efficiently  triggered by anti-CD3 mAbs. 
Triggering of Cytolytic Activity by Anti-CD69 mAbs in Thymo- 
cyte Populations  and Clones.  As shown by previous studies, 
CD69 antigen is constitutively expressed on a subset of freshly 
isolated thymocytes that display bright CD3 fluorescence (28). 
Cells belonging to this subset were also characterized by the 
mutually exclusive expression of CD4 and CD8 antigens, a 
characteristic  of the mature TCR a/3 + thymocyte popula- 
tions. Anti-CD69 mAbs did not induce cytolytic activity of 
these thymocytes against P815 target cells. These data are not 
surprising since these cells belong to the TCR ot/[3 + subset 
(not shown). Also CD69-  thymocytes were shown to ex- 
press surface CD69 antigen after activation in culture (28). 
Therefore, we analyzed a series of thymocyte populations and 
clones expressing different surface phenotypes for their re- 
sponses to anti-CD69 mAb. Since all of these cultured thymo- 
cytes expressed cytolytic activity (19, 23, 29), they could be 
analyzed in redirected killing assays (using P815 target cells) 
for their responsiveness  to anti-CD69 mAbs. Similarly  to 
clones derived from PB, thymocyte clones expressing TCR 
o~/fl were unresponsive, whereas those expressing TCR 3'/~ 
were efficiently triggered by anti-CD69 mAbs (not shown). 
We next analyzed CD3-4-8-7 + thymocyte populations 
expanded in culture as previously described (23). These cells 
expressed cytoplasmic CD3 molecules, thus suggesting that 
they belong to an early stage of thymocyte differentiation 
Table  2.  Effect of mAbs on the Cytolytic Activity of Thymocyte 
Populations or Clones Bearing the CD3-4-8-7 § Surface Phenotype 
Stimuli added to the cytolytic test* 
Anti-CD69 
Effector 
cells  None  PHA  31C4 MLR3  Anti-CD3  Anti-CD16 
Th41*  205  45  56  50  21  21 
ThS0  26  56  50  ND  25  25 
25A6  20  55  70  ND  21  20 
10B9  4  70  60  55  3  2 
* The mAbs used in this  experiment were represented  by KD1 (anti- 
CD16), JT3A (anti-CD3), 31C4 (anti-CD69),  andMLR3 (CD69), used 
at a final concentration of 1 ng/ml. PHA was  used at  a final dilution 
of 1:1,000  vol/vol. 
Effector  cells were either bulk  populations  of activated  thymocytes 
(Th41 and Th50) or thymocyte clones (25A6 and 10B9). In all instances 
these cells expressed  the CD3-4-8-16-7+  surface phenotype. 
5Data  are expressed as a percent  specific SlCr release at an E/T ratio of 
2:1. 
(23). In addition to surface CD3, they lack other surface mol- 
ecules involved in cell triggering including CD16 and CD2 
molecules. Table 2 shows two polyclonal cell lines and two 
clones derived from this thymocyte population. It can be seen 
that anti-CD69 mAbs triggered a strong cytolytic response, 
comparable to that induced by PHA. As expected, neither 
anti-CD3 nor anti-CD16 mAbs could induce target cell lysis. 
Taken together, our data provide evidence that CD69 an- 
tigens represent a triggering surface molecule in different types 
of cultured cytolytic lymphocytes, with the exception of TCR 
a/fl + cells. In a previous report, Testi et al. (16) could not 
detect induction of cytolytic activity by the anti-CD69 Leu23 
mAb. However, these data are not in contrast with our present 
findings since the cytolytic cells used by these authors were 
TCR  oJfl + clones. 
Although not shown, triggering of cytolytic activity was 
also obtained using anti-CD69-producing hybridomas as "trig- 
gering targets". Thus, all types ofcytolytic effector cells ana- 
lyzed mediated lysis of the hybridoma target ceils with the 
exception of TCR oe/[3 + cytolytic clones. These data indi- 
cate that triggering of cytolytic activity mediated by anti- 
CD69 mAbs (similar to most other known pathways of lym- 
phocyte activation) can only be detected in experimental con- 
ditions that allow redirected killing (i.e., use of F~R-positive 
target cells, such as P815, or anti-CD69 mAb-producing hy- 
bridoma). On the contrary, anti-CD69 mAbs could not en- 
hance or inhibit the lysis of Fc~R-negative target cells. 
Interestingly, in two distinct CD3- cell populations also 
lacking CD16 surface antigen, cytolytic activity could be trig- 
gered only by anti-CD69 mAbs. Perhaps more importantly, 
in CD3-4-8-7 + thymocyte lines, which also lack all of the 
known activation pathways  functioning in T  or NK cells, 
1396  CD69-mediated Pathway of Lymphocyte  Activation CD69 represented the only surface molecule capable of in- 
ducing efficient cell triggering. These data may suggest a pos- 
sible role of CD69 molecules in the regulation of the antigen- 
independent proliferation occurring in immature thymocyte 
populations. 
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